Why have status epilepticus trials failed: Wrong drugs or wrong trials?
1City St George's, University of London, School of Health and Medical Sciences, Neurosciences Clinical Academic Group, Cranmer Terrace, London SW17 0RE, UK.
Epilepsy & Behavior : E&B
|September 1, 2024
Summary
Despite decades of research, clinical trial outcomes for status epilepticus remain poor. This review examines reasons for trial failures and suggests improvements in trial design and regulatory frameworks for better results.
Area of Science:
- Neurology
- Clinical Trials
- Epilepsy Research
Background:
- Status epilepticus (SE) research has seen increased interest over the past 20 years.
- Despite this, patient outcomes have not improved, and several high-profile trials have failed.
- Reasons for these failures are multifaceted and require careful consideration.
Purpose of the Study:
- To discuss the various reasons behind the failure of status epilepticus clinical trials.
- To review the importance of interpreting trial results within the broader scientific context.
- To examine potential improvements in trial design, regulatory frameworks, and the use of artificial intelligence.
Main Methods:
- Review of recent well-designed, adequately powered studies in established SE.
- Analysis of studies in refractory and super-refractory SE.
- Consideration of lessons learned from other disease areas, including COVID-19 RECOVERY trials.
Main Results:
- Established SE trials, though failing primary endpoints, are influencing clinical practice.
- Trials in refractory and super-refractory SE have yet to yield successful outcomes.
- Significant financial and human costs are associated with unsuccessful SE trials.
Conclusions:
- Interpreting trial results requires considering broader literature, safety, and practical aspects.
- There is a critical need to review regulatory frameworks and adapt trial designs for SE.
- Artificial intelligence tools may offer potential for future trial optimization.
More Related Videos
Related Concept Videos
01:24Arteries of the Lower Limbs
181
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
181
01:20Antiepileptic Drugs: Potassium Channel Activators
150
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
150
01:30Electroconvulsive Therapy
29
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
29
01:13Seizures: Classification
309
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
309
01:14Antiepileptic Drugs: Glutamate Antagonists
300
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
300
01:19Depolarizing Blockers: Pharmocokinetics
315
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
315